136results about "Vector-based foreign material introduction" patented technology

According to the invention, there is provided seed and plants of the corn variety designated CV252827. The invention thus relates to the plants, seeds and tissue cultures of the variety CV252827, and to methods for producing a corn plant produced by crossing a corn plant of variety CV252827 with itself or with another corn plant, such as a plant of another variety. The invention further relates to corn seeds and plants produced by crossing plants of variety CV252827 with plants of another variety, such as another inbred line. The invention further relates to the inbred and hybrid genetic complements of plants of variety CV252827.

The invention provides a genome editing method based on a CRISPR (Clustered Regularly Interspaced Short Palindromic Repeat) system and belongs to the technical field of gene editing. The genome editing method provided by the invention utilizes introns to express guide RNA molecules in the CRISPR genome editing system and adopts a principle that one or more than one tRNA-gRNA or crRNA series unitsare arranged in the introns of an encoded gene, and after the introns form a fusion gene with Cas9 or Cpf1, a promoter can be used for driving. The genome editing method provided by the invention hasthe benefits that a cellular endogenous mRNA splicing system and a cellular endogenous tRNA processing system are skillfully utilized, and other elements are not required to be added, so that not onlyis the safety higher, but also more simplicity can be realized; the synchronous expression of a plurality of guide RNAs with the Cas9 or the Cpf1 is realized by utilizing the one promoter, so that anexisting CRISPR editing system is simplified, moreover, the efficiency and the ability of simultaneously editing multiple target points of the CRISPR editing system are improved.

Described herein are methods of inhibiting M-CSF activity, and, in particular, M-CSF/c-fms dependent cell signaling. In a first embodiment of the invention, one administers to a mammal viral vectors that deliver genes experessing antisense c-fms RNA; in a second embodiment, one induces in vivo production of a high-affinity soluble c-fms protein that competes for non-bound M-CSF; in a third embodiment, one administers a ribozyme-viral vector against c-fms mRNA; and in a fourth embodiment, one administers oligodeoxynucleotides that inhibit expression of c-fms gene product. The methods may be used to treat any disease in which M-CSF activity plays a role, and are particularly effective in treating and preventing atherosclerosis.

Embodiments of the present invention are directed primarily, but not exclusively, to a method for treating and preventing cardiovascular disease by inhibiting receptors to M-CSF. Other embodiments of the present invention include any and all biologic and/or pathobiologic phenomena mediated in whole or in part by M-CSF signaling through its receptor. Pathobiologic phenomena include, but are not limited to, disease entities such as osteoporosis, Alzheimer's disease, diabetes mellitus (Type 1 and/or Type 2), infectious diseases, cancer, and inherited disorders characterized by defects in one or more components in the M-CSF signaling pathway.

The invention is directed to transcription activator-like effector nuclease (TALEN)-mediated DNA editing of disease-causing mutations in the context of the human genome and human cells to treat patients with compromised genetic disorders.

The present invention relates to a safe non-virulent Yersinia enterocolitica mutant strain for delivering heterologous proteins in target cells carrying mutations in at least one of the effector genes yopH, yopO, yopP, yopE, yopM, yopT genes and at least one additional mutation in the invasin genes chosen from yadA and/or inv. The present invention also relates to a safe non-virulent Yersinia enterocolitica mutant strain for delivering heterologous proteins in target cells according to claim 1 carrying mutations in all effector genes yopH, yopO, yopP, yopE, yopM, yopT genes and at least one additional mutation in the invasin genes chosen from yadA and/or inv. The present invention also relates to an expression vector for delivering a heterologous protein into a target cell using a Yersinia enterocolitica mutant strain according to any of the claims 1 to 4, which comprises in the 5' to 3' direction :(a) a promoter of a Yersinia virulon gene, (b) a first DNA sequence encoding a delivery signal from a Yersinia effector protein, operably linked to said promoter; and, (c) a second DNA sequence coding for said heterologous protein, fused in frame to the 3' end of said first DNA sequence. The present invention further relates to methods and compositions comprising (the use of) the afore-mentioned mutant strains and expression vectors.

According to the invention, there is provided a novel soybean variety designated XB49Q07. This invention thus relates to the seeds of soybean variety XB49Q07, to the plants of soybean XB49Q07 to plant parts of soybean variety XB49Q07 and to methods for producing a soybean plant produced by crossing plants of the soybean variety XB49Q07 with another soybean plant, using XB49Q07 as either the male or the female parent.

The invention specifically discloses a tea tree MYB transcription factor CsAN1 and an application thereof in regulation of anthocyanin metabolism. A nucleotide sequence of the tea tree MYB transcription factor CsAN1 is represented as SEQ ID NO:1. CsAN1 is connected with a 35S promoter and then is connected to a pBI121 carrier, meditated transformation of tobaccos is realized by agrobacteria GV3101, meanwhile, the gene as well as genes CsGL3 and CsTTG1 capable of forming compounds with the gene is used for transforming the tobaccos respectively, leaves of overexpressed tobacco plants turn red, anthocyanin content detected by a spectrophotometer is remarkably increased, and two main pigments including cyanidine and delphinidin are detected through HPLC (high performance liquid chromatography).

The invention discloses a 1,3-1,4-beta-glucanase mutant, and belongs to the fields of gene engineering and enzyme engineering. Lysine in the 20th position, 117th position and 165th position of 1,3-1,4-beta-glucanase from Bacillus terquilensis mutates through an overlapping extension PCR method to form serine in order to obtain single mutants K20S, K117S and K165S respectively. The above three mutation sites are integrally mutated to obtain a K20S/K117S/K165S triple mutant enzyme. Four mutant enzymes have higher catalysis activity and better thermal stability. Compared with wild enzymes, the above mutant enzymes are in favor of realizing the industrial application.

Novel MCP-1 splice variant polypeptides and polynucleotides encoding same are provided. Also provided are pharmaceutical compositions comprising the splice variant polypeptides and polynucleotides, vectors and host cells comprising same. The compositions of the present invention are useful to treat various MCP-1 related disorders as well as for diagnosing, determining predisposition and/or prognosis of various disorders.

Transformed microalgae capable of expressing glycosylated polypeptides and methods for producing said transformed microalgae and producing glycosylated polypeptides.

Provided is a novel vector for immunostimulation and methods of using same in immunotherapy, in particular cancer immunotherapy. The novel vector comprises nucleic acid sequences encoding 4-1BB ligand (4-1BBL, CD137 ligand), single chain IL-12 (sc IL-12) and IL-2, wherein the vector provides for an increased expression of 4-1BBL as compared to the expression levels of sc IL-12 and IL-2. Specifically, the nucleic acid sequences encoding 4-1BBL, sc IL-12 and IL-2 are organized in the vector in 5′ to 3′ orientation in a sequential order 1, 2, 3, with the proviso that the gene encoding sc IL-12 is not at position 1. Embodiments of the present disclosure include virus particles comprising the novel vector as well as cancer or immune cells transduced or transfected with the novel vector.

Genetically modified lactic acid bacteria having a reduced or lacking or enhanced diacetyl reductase activity, acetoin reductase activity and/or butanediol dehydrogenase activity are provided. Such bacteria are used in starter cultures in the production of food products including dairy products where it is desired to have a high content of diacetyl and for reducing or completely removing diacetyl in beverages including beers, fruit juices and certain types of wine, where the presence of diacetyl is undesired.

A novel protein having inhibitory activity on the protease activity of hepatocyte growth factor (HGF) activator was purified and isolated, and its molecular weight (ca. 40,000 daltons) and its N-terminal and partial amino acid sequences were determined. A gene coding for the protein was cloned, and the gene DNA was incorporated into a vector, for transforming host cells. Cultivation of the transformant gave the desired protein. The protein can be used as an in vivo or in vitro control factor for HGF or HGF activator. It is also useful as an antigen to be used in producing an antibody to be used as means for kinetic studies of the protein, or as a standard in assay systems therefor.

The invention belongs to the field of microbial genetic engineering, and discloses a GTP cyclohydrolase I gene folE and application. A nucleotide sequence of the GTP cyclohydrolase I gene folE is shown as SEQ ID NO:1. The gene is derived from food-borne lactobacillus plantarum, is safe and can be used in the field of later-stage food fermentation. A gene knockout strain screening method can be used for improving the screening efficiency of knockout strains. The key role of gene folE gene in folic acid synthesis is proved, and a certain theoretical basis is provided for the research and development of folic acid synthesis functional food. The GTP cyclohydrolase I gene folE and application analyze that the gene is derived from food-grade microorganisms and is safe; and the GTP cyclohydrolaseI gene folE and application analyze that the gene folE gene has nothing to do with cell morphology and strain growth except playing an important role in folic acid synthesis.

This invention provides a method for accelerating the proliferation of human mesenchymal stem cells, which comprises the steps of: transfecting recombinant expression carrier containing EGF to human mesenchymal stem cells, and stimulating with a certain concentration of calcium ions during the transfection process to divide into typical stem cells. Under nude mouse subcutaneous microenvironment induction, the stem cells are further divided into skin tissue stem cells, thus directly taking part in the proliferation of nude mouse hair. This invention can obtain rapidly proliferated human mesenchymal stem cells, thus having a potential application in clinical skin wound treatment.

The invention discloses a vector for knocking out an L-lactic dehydrogenase 1 gene and a construction method of the vector. The construction method comprises the following steps: completely splicing upstream and downstream DNA fragments of a gene which does not contain an L-lactic dehydrogenase encoding gene by using an overlapping extension process, also cloning the spliced fragments to a sub-vector pMD18-T and transforming the spliced fragments to escherichia coli DH5alpha competent cells, screening constructed sub-cloning vectors by virtue of blue-white spots, performing double enzyme digestion to obtain a target strip, then connecting the target strip to a pG+host9 plasmid, and performing bacterial colony PCR and double enzyme digestion identification to successfully obtain a recombinant vector. According to the vector and the construction method thereof disclosed by the invention, a recombinant plasmid of which the L-lactic dehydrogenase encoding genes are knocked out is constructed by using an overlapping extension PCR process, so that excessive base sequences introduced by enzyme digestion and connection can be avoided; and the recombinant vector disclosed by the invention can be used for producing D-lactic acid with high optical purity.

A recombinant vector for delivering A3G genes into human cells comprising (i) a gene expression block including an A3G gene selected from a wild type A3G gene represented by SEQ ID NO: 1 and a mutant A3G gene and (ii) a group of elements from a modified lentiviral vector including lentiviral regions of packaging signal (ψ, psi), LTRs, RRE, and PBS; wherein said A3G gene is operably linked to the packaging signal (ψ, psi), LTRs, RRE, and PBS.

The invention belongs to the field of biological medicine, and relates to a long-acting HIV fusion inhibitor for treating acquired immune deficiency syndrome and application thereof. The long-acting HIV fusion inhibitor comprises a polypeptide part for inhibiting HIV membrane fusion and a part capable of being specifically combined with human immune globulin Fc, it is proved through experiments that the half-life period of the long-acting HIV fusion inhibitor in a rhesus monkey is about 11 times that of the HIV fusion inhibitor T20 which is first approved for marketing and has excellent antiviral activity to HIV-1IIIB and HIV-1Bal, the IC50 values are about 5.9 nM and 2.57 nM respectively, the antiviral activity is about 3 times that of T20, and the long-acting HIV fusion inhibitor has low toxicity to cells. The long-acting HIV fusion inhibitor IBP-CP24 polypeptide can be used for preparing a drug for resisting human immunodeficiency viruses for a long time and providing a new strategy for prolonging the half-life period of protein and polypeptide drugs in the body.

Compositions and methods for protecting a plant from an insect pest are provided. In particular, nucleic acid sequences encoding insect protoxins modified to comprise at least one proteolytic activation site that is sensitive to a plant protease or an insect gut protease are provided. Cleavage of the modified protoxin at the proteolytic activation site by a protease produces an active insect toxin. Methods of using the modified insect protoxin nucleic acid sequences and the polypeptides they encode to protect a plant from an insect pest are provided. Particular embodiments of the invention further provide modified insect protoxin compositions and formulations, expression cassettes, and transformed plants, plant cells, and seeds.